Filtered By:
Specialty: Hematology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 1625 results found since Jan 2013.

DNA Methylation and Ischemic Stroke Risk: An Epigenome-Wide Association Study
CONCLUSION: Specific DNA methylation pattern is causally associated with IS risk. These results could be useful for specifically predicting stroke occurrence and could potentially be evaluated as therapeutic targets.PMID:35717949 | DOI:10.1055/s-0042-1749328
Source: Thrombosis and Haemostasis - June 19, 2022 Category: Hematology Authors: Natalia Cullell Carolina Soriano-T árraga Cristina Gallego-F ábrega Jara C árcel-Márquez Nuria P Torres- Águila Elena Mui ño Miquel Lled ós Laia Lluci à-Carol Manel Esteller Manuel Castro de Moura Joan Montaner Alba Fern ández-Sanlés Roberto Elo Source Type: research

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research

Stroke and myocardial infarction in patients with abdominal aortic aneurysms and new-onset atrial fibrillation
Conclusion Cardiovascular prognosis has improved in patients with prevalent AAA disease and new-onset AF in concordance with optimization of antithrombotic therapy over time. A diagnosis of AF conferred residual risk of stroke and myocardial infarction.PMID:36626930 | DOI:10.1055/a-2009-8954
Source: Thrombosis and Haemostasis - January 10, 2023 Category: Hematology Authors: Chalotte Winther Winther Nicolajsen Peter Br ønnum Nielsen Martin Jensen Nikolaj Eldrup Torben Bjerregaard Larsen Gregory Yh Lip Samuel Z Goldhaber Mette S øgaard Source Type: research

Coagulation biomarkers for ischemic stroke
We report on coagulation biomarker-induced risk of IS, stroke severity, and outcomes following IS derived from prospective population studies, case-control studies, and acute-phase IS studies. We found indications that many coagulation and inflammation biomarkers are associated with IS, but it is early to conclude that any of these biomarkers can be applied in a therapeutic setting to predict patients at risk of IS, stroke severity at the acute phase, and clinical outcome after treatment. The strongest evidence for a role in IS was found for beta-thromboglobulin, von Willebrand factor, factor VIII, fibrinogen, thrombin-act...
Source: Thrombosis and Haemostasis - June 5, 2023 Category: Hematology Authors: Aarazo Barakzie A J Gerard Jansen Hugo Ten Cate Moniek P M de Maat Source Type: research

Munc13‐4 mediated secretion is essential for infarct progression but not intracranial haemostasis in acute stroke
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 9, 2013 Category: Hematology Authors: David Stegner, Carsten Deppermann, Peter Kraft, Martina Morowski, Christoph Kleinschnitz, Guido Stoll, Bernhard Nieswandt Tags: Letter ‐ to the Editor Source Type: research

Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants
New orally administered anticoagulants will simplify stroke-prevention strategies in patients with atrial fibrillation (AF). Novel anticoagulants, such as dabigatran etexilate, a direct thrombin inhibitor, and rivaroxaban, a direct factor Xa inhibitor, have been approved by the US Food and Drug Administration for the prevention of stroke and systemic embolism in patients with nonvalvular AF. In addition, the factor Xa inhibitor apixaban has been reported to be as effective as warfarin in a large, randomized clinical trial, and the efficacy of edoxaban is being assessed in a phase III warfarin comparison trial. This review ...
Source: Clinical and Applied Thrombosis/Hemostasis - June 3, 2013 Category: Hematology Authors: Haft, J. I. Tags: Review Source Type: research

Improving Prediction of Recanalization in Acute Large Vessel Occlusive Stroke.
CONCLUSIONS: Acute endovascular treatment is the single most important factor promoting recanalization in acute ischemic stroke. Presence of extracranial vessel stenosis or occlusion decreases recanalization rates. In patients with intracranial occlusions, higher NIHSS and ASPECTS and normal vigilance facilitate recanalization. Integration in treatment algorithms could influence recanalization strategies in individual patients. This article is protected by copyright. All rights reserved. PMID: 24628853 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 15, 2014 Category: Hematology Authors: Vanacker P, Lambrou D, Eskandari A, Maeder P, Meuli R, Ntaios G, Michel P Tags: J Thromb Haemost Source Type: research

Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States
Abstract This retrospective analysis investigated the impact of baseline clinical characteristics, including atrial fibrillation (AF), on hospital discharge status (to home or continuing care), mortality, length of hospital stay, and treatment costs in patients hospitalized for stroke. The analysis included adult patients hospitalized with a primary diagnosis of ischemic or hemorrhagic stroke between January 2006 and June 2011 from the premier alliance database, a large nationally representative database of inpatient health records. Patients included in the analysis were categorized as with or without AF, based on...
Source: Journal of Thrombosis and Thrombolysis - November 5, 2014 Category: Hematology Source Type: research

Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke
Stroke is the second most common cause of mortality in the world today, where transient ischemic attack (TIA) is a period of focal ischemia, the symptoms of which resemble a thromboembolic stroke. Contrary to stroke, TIA symptoms typically last less than one hour and necrosis is absent. Stroke is often preceded by TIA, making it an important predictor of future ischemic events. The causal role of atherosclerosis in the development of TIA is well established, however, research indicates that the atherosclerotic process begins years earlier with the development of metabolic syndrome, which affects approximately 45% of the ad...
Source: Thrombosis Research - January 16, 2015 Category: Hematology Authors: Mia-Jeanne van Rooy, Etheresia Pretorius Tags: Review Article Source Type: research

The prediction of postoperative stroke or death in patients with preoperative atrial fibrillation undergoing non‐cardiac surgery: a VISION sub‐study
ConclusionsIn AF patients, the 3 thromboembolic risk scores performed similarly to the RCRI in predicting death within 30 days and the CHADS2 score was the best predictor of postoperative stroke/death regardless of type of surgery.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - August 13, 2015 Category: Hematology Authors: Finlay A. McAlister, Michael Jacka, Michelle Graham, Erik Youngson, George Cembrowski, Sean M. Bagshaw, Neesh Pannu, Derek R. Townsend, Sadeesh Srinathan, Pablo Alonso‐Coello, P J Devereaux Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Stroke in atrial fibrillation and improving the identification of 'high risk' patients: the crossroads of immunity and thrombosis.
This article is protected by copyright. All rights reserved. PMID: 26303061 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 25, 2015 Category: Hematology Authors: Shantsila E, Lip GY Tags: J Thromb Haemost Source Type: research

Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency
Stroke is defined as a focal or global disturbance of cerebral function lasting over 24h; resulting from disruption of blood supply [1]. Stroke during pregnancy is fortunately a rare event, but it can have severe consequences, such as long-term disability or death, with 9.5% of all maternal deaths being related to stroke [2]. The overall risk of pregnancy-related stroke was 34.2 (95% CI 33.3–35.1) per 100000 deliveries in the USA, with 48% occurring postpartum, 41% at the time of delivery and 11% antepartum [3].
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Mirjana Kovac, Gorana Mitic, Zeljko Mikovic, Vesna Mandic, Valentina Djordjevic, Laszlo Muszbek, Zsuzsanna Bereczky Tags: Correspondence Source Type: research